227.46 0.00 (0.00%)
After hours: 4:51PM EDT
|Bid||228.37 x 1000|
|Ask||230.25 x 1200|
|Day's Range||227.29 - 229.67|
|52 Week Range||136.44 - 230.19|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||66.65|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||221.97|
Top-line growth, expected increase in bookings and solid show by Population Health, Revenue Cycle and IT Works are anticipated to get reflected in Cerner's (CERN) Q3 earnings.
Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW), based in Irvine, Ca., makes heart valve systems and repair products for a patient's diseased or defective heart valve, notes breakout stock specialist Leo Fasciocco, editor of Ticker Tape Digest.
Better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth are likely to aided Intuitive Surgical (ISRG) in Q3 earnings.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
IRVINE, Calif. , Oct. 9, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...
Sometimes, two bases are better than one. That's why the base-on-base pattern, which links two distinct and sound bases, often leads to big winners.
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. Study results were presented as a late-breaking clinical trial at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, and simultaneously published online to the Journal of the American College of Cardiology. The new 1-year data, involving approximately 1,000 patients enrolled in the PARTNER 3 Trial, showed significant improvements in health status as well as overall physical and mental well-being after treatment with either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 valve or surgical aortic valve replacement.
If you want to know who really controls Edwards Lifesciences Corporation (NYSE:EW), then you'll have to look at the...
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
Edwards Lifesciences (EW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).